Related Experiment Video
Updated: May 7, 2026
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Network pharmacology approach and experimental validation of Lamei pills in treating ischemic stroke based on
Caolong Li1, Chengyan Liu2, Yuanzheng Xia2
1Tibetan Medicine Research Institute, University of Tibetan Medicine, Tibet, 850000, PR China; Department of Chemistry, School of Science, China Pharmaceutical University, Nanjing, 211198, PR China.
Ethnopharmacological Relevance:
Lamei Pills (LMP), commonly referred to as the "Twenty-Four Ingredient Agilawood Pill," originated from the "Eight Ingredient Agilawood Pill" documented in the 8th-century Tibetan medical text "The Four Tantras". LMP primarily used for treating neurological and cerebrovascular diseases. However, the material basis and therapeutic mechanisms of LMP in ischemic stroke (IS) remain inadequately elucidated.
Aim Of The Study:
This study aims to elucidate the material basis and target network of LMP in treating IS through MS technology, network pharmacology and experimental verification.
Materials And Methods:
UHPLC-Q-Exactive Orbitrap-MS was utilized to identify the chemical constituents of LMP. Network pharmacology was employed to analyze candidate targets and signaling pathways associated with LMP in IS treatment. Additionally, molecular docking and animal experiments were conducted to validate its therapeutic efficacy and underlying mechanisms.
Results:
Mass spectrometry identified 3657 chemical components, with 50 potential active components screened for target prediction. Through protein-protein interaction (PPI) analysis, kyoto encyclopedia of genes and genomes (KEGG), and gene ontology (GO) enrichment analysis, 20 core common targets between LMP and IS were identified. A drug-component-target-pathway-disease network was constructed, and molecular docking revealed that progesterone exhibited the lowest binding energy with AKT1. Animal experiments demonstrated that LMP significantly alleviated neurological deficits, reduced cerebral infarction area, and effectively inhibited neuronal apoptosis in middle cerebral artery occlusion (MCAO) rats. Immunofluorescence staining and Western blot further confirmed that LMP exerted neuroprotective effects via the PI3K/AKT, TLR4/NF-κB, STAT3, and TNF-α signaling pathways.
Conclusion:
This study systematically elucidated the material basis, associated signaling pathways, and potential targets of LMP in IS treatment, providing a scientific foundation for its clinical application.
